News Sentiment

GLMD sentiment intelligence

Galmed Pharmaceuticals Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.55 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-2.5% over one week, -5.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Galmed unveils heart-targeted Aramchol in cardiac fibrosis push

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.5% Price reacting lower
Trend fit Trend inactive -5.9% over four weeks
Fair value -82.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 36
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 10
PR Newswire 9
Market source 7
Investing.com Nigeria 3
timothysykes.com 3
Investing.com 2
dars.gov.et 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 16
Deals and strategy 11
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Indian Pharma Post Direct company coverage

Galmed unveils heart-targeted Aramchol in cardiac fibrosis push

Galmed Pharmaceuticals has developed a new lipid nanoparticle (LNP) formulation of its drug Aramchol, designed to selectively target heart tissue for treating cardiac fibrosis. This innovation, in collaboration with Barcode Nanotech, aims to overcome delivery challenges by redire

Tone
Positive 74/100
Event
Analyst action
Published
19 Jul 2026 07:11
Source
Indian Pharma Post
Stock Titan Direct company coverage

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) tests heart-targeted Aramchol LNPs

Galmed Pharmaceuticals (NASDAQ: GLMD) announced a breakthrough in developing a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, that specifically targets heart tissue. This new formulation aims to redirect Aramchol's biodistribution away from the liver

Tone
Positive 67/100
Event
Market update
Published
16 Jul 2026 19:40
Source
Stock Titan
Investing.com Direct company coverage

Galmed develops heart-targeted formulation of Aramchol drug

Galmed Pharmaceuticals Ltd. announced the development of a heart-targeted formulation of its drug Aramchol, in collaboration with Barcode Nanotech. This new lipid nanoparticle formulation aims to redirect Aramchol from the liver to heart muscle tissue to address cardiac fibrosis,

Tone
Positive 71/100
Event
Market update
Published
16 Jul 2026 19:11
Source
Investing.com
Investing.com Nigeria Direct company coverage

Galmed develops heart-targeted formulation of Aramchol drug By Investing.com

Galmed Pharmaceuticals Ltd. announced the development of a heart-targeted formulation of its drug Aramchol, in collaboration with Barcode Nanotech. This new formulation uses lipid nanoparticles to redirect 80-90% of the drug's biodistribution from the liver to heart muscle tissue

Tone
Positive 72/100
Event
Market update
Published
16 Jul 2026 18:11
Source
Investing.com Nigeria
Market source Direct company coverage

Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD)

Galmed (NASDAQ:GLMD) has developed a new cardiac-targeted formulation of Aramchol, its SCD1 inhibitor, using lipid nanoparticles in collaboration with Barcode Nanotech. This innovation aims to redirect the drug from the liver to the heart, expanding its potential application beyo

Tone
Positive 66/100
Event
Market update
Published
16 Jul 2026 14:05
Source
Market source
PR Newswire Direct company coverage

Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

Galmed Pharmaceuticals Ltd. has announced the development of a new lipid nanoparticle (LNP) formulation of its SCD1 inhibitor, Aramchol, designed for targeted delivery to the heart. This breakthrough, developed in collaboration with Barcode Nanotech, aims to redirect Aramchol's e

Tone
Positive 75/100
Event
Market update
Published
16 Jul 2026 11:10
Source
PR Newswire
Stock Titan Direct company coverage

Galmed (NASDAQ: GLMD) posts Q1 loss and closes Colospan acquisition

Galmed Pharmaceuticals (GLMD) reported a widened net loss of $1.9 million in Q1 2026, primarily due to increased research and development spending. Despite holding $15.6 million in current assets, the company anticipates needing substantial additional funding for its programs. Po

Tone
Negative 33/100
Event
Deals and strategy
Published
08 Jul 2026 20:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Galmed Pharmaceuticals (Nasdaq:GLMD) - Stock Analysis

Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) is a biopharmaceutical company focused on liver diseases, with a market cap of US$3.8 million. The company faces significant risks including volatile share price, projected earnings decline, substantial shareholder dilution, and low reven

Tone
Negative 39/100
Event
Earnings
Published
02 Jul 2026 02:09
Source
Simply Wall Street
The Globe and Mail Direct company coverage

Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure

Galmed Pharmaceuticals has closed its amended all-cash acquisition of Colospan Ltd., substituting a stock issuance with an additional $800,000 in cash, bringing the total cash at closing to $3.3 million. The deal now includes a performance-based earnout of up to $2.0 million and

Tone
Negative 38/100
Event
Deals and strategy
Published
27 Jun 2026 04:09
Source
The Globe and Mail
TradingView Direct company coverage

Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD)

This article provides an overview of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), covering its stock performance, financial data, and analyst estimates. Key information includes the current stock price, historical highs and lows, market capitalization, upcoming earnings report date

Tone
Negative 28/100
Event
Earnings
Published
26 Jun 2026 23:11
Source
TradingView
TradingView Direct company coverage

GLMD Forecast — Price Target — Prediction for 2027

This article provides an overview of Galmed Pharmaceuticals Ltd. (GLMD) stock performance, financial data, and analyst ratings. It highlights the stock's recent price decrease, its all-time high and low prices, market capitalization, and upcoming earnings report. The article also

Tone
Negative 29/100
Event
Analyst action
Published
26 Jun 2026 13:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD

This article provides a brief overview of the "Price to sales forward" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) on the TradingView platform. It indicates that the market was closed with no trades recorded at the time of publication, and it displays a table showing th

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 12:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD

This article provides a financial statistic for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). Specifically, it highlights the company's enterprise value to EBIT forward. The article is part of a larger financial data platform.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 01:39
Source
TradingView
TradingView Direct company coverage

GPH Forecast — Price Target — Prediction for 2027

This article provides a forecast for Galmed Pharmaceuticals Ltd. (GPH) stock, including historical price data, upcoming earnings reports, and financial metrics. It highlights that GPH does not pay dividends and details how to track its financial performance and trade its shares.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD

This article focuses on the "Enterprise value to revenue forward" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). It appears to be a financial snapshot or a report from TradingView, providing specific financial data points for the company. The content itself seems to be a

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Price to book forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD

This article provides the "Price to Book Forward" value for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD). It indicates that the specific financial data point was "Made by humans" and references the stock's market on TradingView.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD

This article focuses on the "Price to earnings forward" metric for Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) as presented on TradingView. It appears to be a financial data point rather than an in-depth analysis, showing the value and changes over a period. The content primarily

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD

This page from TradingView provides financial information for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), specifically focusing on its enterprise value to EBITDA forward. It indicates various data sources and copyrights for the financial information presented.

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 03:39
Source
TradingView
Stock Titan Direct company coverage

Galmed buys CG-100 maker Colospan, eyes faster EU sales

Galmed Pharmaceuticals has completed its acquisition of Colospan, gaining the CE-marked CG-100 device for colorectal procedures, which is commercial-ready in the EU and Israel with a dedicated German OPS code. The restructured deal replaces a $2.0 million share issuance with an $

Tone
Positive 65/100
Event
Deals and strategy
Published
22 Jun 2026 23:40
Source
Stock Titan
Stock Titan Direct company coverage

Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) has finalized its acquisition of Colospan Ltd., a medical device company, with revised financial terms. The deal includes $3.3 million in cash at closing and a performance-based earnout of up to $2 million, replacing a previous plan for

Tone
Positive 70/100
Event
Deals and strategy
Published
22 Jun 2026 22:11
Source
Stock Titan
Investing.com Direct company coverage

Galmed completes acquisition of medical device firm Colospan

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has finalized its acquisition of Colospan Ltd., a medical device company, following a restructuring of the deal terms. The revised agreement includes an increased cash payment and an earnout structure tied to net sales, aiming to reduce i

Tone
Positive 61/100
Event
Deals and strategy
Published
22 Jun 2026 21:12
Source
Investing.com
grafa.com Direct company coverage

Galmed Pharmaceuticals finishes restructured Colospan deal

Galmed Pharmaceuticals has completed its acquisition of medical device company Colospan, finalizing restructured terms that replaced a $2 million share issuance with an $800,000 cash payment. The deal also includes an earnout of up to $2 million beginning in Q3 2027 and grants Ga

Tone
Negative 39/100
Event
Deals and strategy
Published
22 Jun 2026 15:09
Source
grafa.com
Investing.com Nigeria Direct company coverage

Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com

This article announces that Galmed Pharmaceuticals Ltd. filed a Form 6-K on June 22. The filing is brief, providing only the date and the company name. Galmed Pharmaceuticals Ltd. (GLMD) stock experienced a -2.76% change according to the article's financial data.

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 12:10
Source
Investing.com Nigeria
TradingView Direct company coverage

Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd.

Galmed Pharmaceuticals Ltd. has announced restructured acquisition terms for Colospan Ltd. This brief press release from Refinitiv was published via TradingView News. The full details of the restructured terms are not provided in this short article.

Tone
Neutral 50/100
Event
Deals and strategy
Published
22 Jun 2026 12:09
Source
TradingView